397 related articles for article (PubMed ID: 25871646)
1. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.
Kaddurah-Daouk R; Weinshilboum R;
Clin Pharmacol Ther; 2015 Jul; 98(1):71-5. PubMed ID: 25871646
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics enables precision medicine: "A White Paper, Community Perspective".
Beger RD; Dunn W; Schmidt MA; Gross SS; Kirwan JA; Cascante M; Brennan L; Wishart DS; Oresic M; Hankemeier T; Broadhurst DI; Lane AN; Suhre K; Kastenmüller G; Sumner SJ; Thiele I; Fiehn O; Kaddurah-Daouk R;
Metabolomics; 2016; 12(10):149. PubMed ID: 27642271
[TBL] [Abstract][Full Text] [Related]
3. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.
Katsila T; Matsoukas MT; Patrinos GP; Kardamakis D
OMICS; 2017 Aug; 21(8):429-439. PubMed ID: 28816643
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics: a global biochemical approach to drug response and disease.
Kaddurah-Daouk R; Kristal BS; Weinshilboum RM
Annu Rev Pharmacol Toxicol; 2008; 48():653-83. PubMed ID: 18184107
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics as a tool for drug discovery and personalised medicine. A review.
Mastrangelo A; Armitage EG; García A; Barbas C
Curr Top Med Chem; 2014; 14(23):2627-36. PubMed ID: 25515755
[TBL] [Abstract][Full Text] [Related]
6. Metabolome 2.0: quantitative genetics and network biology of metabolic phenotypes.
Dumas ME
Mol Biosyst; 2012 Oct; 8(10):2494-502. PubMed ID: 22868675
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics.
Mussap M; Loddo C; Fanni C; Fanos V
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):115-134. PubMed ID: 31958027
[No Abstract] [Full Text] [Related]
8. Delivering systems pharmacogenomics towards precision medicine through mathematics.
Wang Y; Wang N; Wang J; Wang Z; Wu R
Adv Drug Deliv Rev; 2013 Jun; 65(7):905-11. PubMed ID: 23523629
[TBL] [Abstract][Full Text] [Related]
9. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Fleisher B; Brown AN; Ait-Oudhia S
Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
[TBL] [Abstract][Full Text] [Related]
10. Using quantitative systems pharmacology for novel drug discovery.
Pérez-Nueno VI
Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
[TBL] [Abstract][Full Text] [Related]
11. Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean.
Bafiti V; Katsila T
OMICS; 2022 Oct; 26(10):542-551. PubMed ID: 36149303
[TBL] [Abstract][Full Text] [Related]
12. Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.
Beger RD; Schmidt MA; Kaddurah-Daouk R
Metabolites; 2020 Mar; 10(4):. PubMed ID: 32230776
[TBL] [Abstract][Full Text] [Related]
13. [An introduction to QSP modeling for pharmacologists].
Sayama H; Nagasaka Y; Tabata K
Nihon Yakurigaku Zasshi; 2019; 154(3):143-150. PubMed ID: 31527365
[TBL] [Abstract][Full Text] [Related]
14. A Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease Phenotypes.
Schurdak ME; Pei F; Lezon TR; Carlisle D; Friedlander R; Taylor DL; Stern AM
Methods Mol Biol; 2018; 1787():207-222. PubMed ID: 29736721
[TBL] [Abstract][Full Text] [Related]
15. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
Kaddurah-Daouk R; Weinshilboum RM;
Clin Pharmacol Ther; 2014 Feb; 95(2):154-67. PubMed ID: 24193171
[TBL] [Abstract][Full Text] [Related]
16. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Agoram BM; Demin O
Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
[TBL] [Abstract][Full Text] [Related]
17. Pharmacometabolomics informs Pharmacogenomics.
Neavin D; Kaddurah-Daouk R; Weinshilboum R
Metabolomics; 2016 Jul; 12(7):. PubMed ID: 27516730
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen integromics and personalized medicine: dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment.
Dimitrakopoulou K; Dimitrakopoulos GN; Sgarbas KN; Bezerianos A
OMICS; 2014 Jan; 18(1):15-33. PubMed ID: 24299457
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics: moving to the clinic.
Nordström A; Lewensohn R
J Neuroimmune Pharmacol; 2010 Mar; 5(1):4-17. PubMed ID: 19399626
[TBL] [Abstract][Full Text] [Related]
20. Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study.
Combrink M; du Preez I; Ronacher K; Walzl G; Loots DT
OMICS; 2019 Nov; 23(11):560-572. PubMed ID: 31613685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
